NASD · Healthcare · Biotechnology · USA
Ligand Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Ligand Pharmaceuticals acquires and structures royalty streams from biopharmaceutical products in development or on the market, generating revenue from royalties on partner-sold medicines plus sales of platform technologies Captisol and NITRICIL. The company also receives contract revenues from licensing arrangements and milestone payments while maintaining a lean operational structure.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Ligand Pharmaceuticals Inc stock.
Overvalued: intrinsic value $192.40 per share, market price $297.28, margin of safety -54.5% (as of 2026-10-19).
Discounting its cash flows at 10.3% (average of 2 methods) values the shares at $192.40; the price of $297.28 is 55% above that value, and 73% of that value comes from beyond year five.
Leak Score: 30/100 on 11 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
48 more in this industry show a wider margin of safety.
LGND is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 10.3% (average of 2 methods) values the shares at $192.40; the price of $297.28 is 55% above that value, and 73% of that value comes from beyond year five.
$192.40 per share (as of the 2026-10-19 close), against a market price of $297.28. That is a margin of safety of -54.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
30 out of 100, which we rate "On Watch", on 11 of 12 value investing signals.